Edgar Filing: BAFFI ROBERT - Form 4

DAEEL DODEDT

BAFFI ROB	BERT												
Form 4													
November (05, 2010												
FORM 4 UNITED STATES SECURITIES AND EXCHANCE COMMISSION											OMB APPROVAL		
Washington, D.C. 20549										OMB Number:	3235-0287		
Check this box if no longer										Expires:	January 31,		
subject t Section Form 4 o	IENT OF	F CHAN			BENEF ATIES	ICIA	ERSHIP OF	Estimated a burden hour response					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940													
(Print or Type	Responses)												
1. Name and A BAFFI RO		2. Issuer Name and Ticker or Trading Symbol BIOMARIN PHARMACEUTICAL						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
INC [BMRN] (Check									c all applicable)				
				3. Date of Earliest Transaction (Month/Day/Year)					Director 10% Owner X Officer (give title Other (specify below) below)				
C/O BIOMARIN 11/03/2010 below) below) PHARMACEUTICAL INC., 105 DIGITAL DRIVE								ons					
(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)						 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 							
NOVATO CA 94949 —							More than One Reporting						
(City)	(State)	(Zip)	Tabl	le I - No	on-D	Derivative	Secur	rities Acqu	iired, Disposed of,	or Beneficiall	y Owned		
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)			Date, if	3. Transa Code (Instr.		4. Securi n(A) or D (Instr. 3,	spose 4 and	d of (D)	5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)			
				Code	v	Amount	(A) or (D)	Price \$	Transaction(s) (Instr. 3 and 4)				
Common Stock	10/29/2010 <u>(1)</u>	10/29/20)10	А	V	473	А	(2) (11.637	69,713	D			
Common Stock	11/03/2010	11/03/20)10	S		2,000	D	\$ 25.244 (3)	67,713	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of
information contained in this form are not
required to respond unless the formSEC 1474
(9-02)

Edgar Filing: BAFFI ROBERT - Form 4

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	5		7. Titl Amou Under Secur (Instr.	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
BAFFI ROBERT C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO, CA 94949			EVP, Technical Operations					
Signatures								
/s/ Laura Randall Woodhead, Attorney-in-Fact	11/0	5/2010						
**Signature of Reporting Person	D	ate						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's Employee Stock Purchase Program ("ESPP"), for the ESPP purchase period of May 1, 2010 to October 29, 2010.
- (2) In accordance with ESPP, these shares have been purchased at 85% of the closing price of issuer's common stock on April 30, 2010.

The price in Column 4 is a weighted average price. The prices actually received range from \$25.24 to \$25.251. The reporting person will(3) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.